The batch of Form 3 filings is a definitive signal that Braveheart Bio's IPO is imminent. Traders should prepare for the S-1 registration statement and IPO pricing. The presence of top-tier healthcare investors OrbiMed and Andreessen Horowitz as anchor holders is a strong positive signal for IPO demand. Monitor for the S-1 filing and roadshow announcements.
Price Chart
Executive Summary
Braveheart Bio, Inc. (BRVE) filed a batch of 11 Form 3 initial beneficial ownership reports on August 5, 2026, signaling an upcoming IPO. The filings disclose major pre-IPO investors: OrbiMed Advisors (via OrbiMed Private Investments IX, LP) holds 9,132,420 shares of common stock on a converted basis from Series A Preferred, plus 1,102,739 shares of common stock; Andreessen Horowitz's AH Bio Fund IV, L.P. holds 9,132,420 shares of common stock on a converted basis from Series A Preferred. Additionally, the company's CFO James Paul Rickey disclosed direct ownership of 493,150 shares, and director/chairman Christopher Viehbacher disclosed direct ownership of 526,186 shares. The simultaneous filing of initial ownership statements by all major insiders and institutional investors is a strong signal that Braveheart Bio is preparing to go public imminently, with the Series A Preferred Stock converting automatically into common stock immediately prior to the closing of the IPO.
Key Facts
- Braveheart Bio filed a batch of 11 Form 3 initial statements of beneficial ownership on August 5, 2026, indicating an imminent IPO.
- OrbiMed Advisors (via OrbiMed Private Investments IX, LP) holds 9,132,420 shares of common stock on a converted basis from Series A Preferred, plus 1,102,739 shares of common stock.
- Andreessen Horowitz's AH Bio Fund IV, L.P. holds 9,132,420 shares of common stock on a converted basis from Series A Preferred.
- CFO James Paul Rickey directly owns 493,150 shares of common stock.
- Director/Chairman Christopher Viehbacher directly owns 526,186 shares of common stock.
- Series A Preferred Stock converts to Common Stock on a one-for-4.38 basis automatically at the IPO closing.
- OrbiMed has designated Erez Chimovits to serve on Braveheart Bio's board of directors.
Financial Impact
Pre-IPO ownership structure disclosed; no offering price or size provided.
Risk Factors
- IPO pricing and market reception are unknown; pre-IPO valuations not disclosed.
- No financial performance data or pipeline details are available in these filings.
- Lock-up agreements and post-IPO dilution from the conversion of preferred shares are not detailed here.
Documents Analyzed
This report is based on 44 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (BRVE) — Batch item 1 | 0000947871-26-000749 |
| Document: 0000947871-26-000749-index.html | 0001231919-26-000833 |
| Document: 0000947871-26-000749.txt | 0001470831-26-000780 |
| 3 Filing (BRVE) — Batch item 4 | 0001231919-26-000833 |
| Exhibit: ex24-08062026_010812.htm | 0001470831-26-000778 |
| Document: 0001231919-26-000833-index-headers.html | 0001470831-26-000777 |
| Document: 0001231919-26-000833-index.html | 0000947871-26-000749 |
| Document: 0001231919-26-000833.txt | 0001231919-26-000833 |
| 3 Filing (BRVE) — Batch item 9 | 0001470831-26-000780 |
| Document: 0001470831-26-000780-index-headers.html | 0001470831-26-000779 |
| Document: 0001470831-26-000780-index.html | 0001470831-26-000778 |
| Document: 0001470831-26-000780.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 13 | 0001470831-26-000779 |
| Document: 0001470831-26-000779-index-headers.html | 0000947871-26-000749 |
| Document: 0001470831-26-000779-index.html | 0000947871-26-000749 |
| Document: 0001470831-26-000779.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 17 | 0001470831-26-000778 |
| Document: 0001470831-26-000778-index-headers.html | 0000947871-26-000749 |
| Document: 0001470831-26-000778-index.html | 0000947871-26-000749 |
| Document: 0001470831-26-000778.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 21 | 0001470831-26-000777 |
| Document: 0001470831-26-000777-index-headers.html | 0000947871-26-000749 |
| Document: 0001470831-26-000777-index.html | 0000947871-26-000749 |
| Document: 0001470831-26-000777.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 25 | 0000947871-26-000749 |
| Document: 0000947871-26-000749-index.html | 0000947871-26-000749 |
| Document: 0000947871-26-000749.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 28 | 0001231919-26-000833 |
| Exhibit: ex24-08062026_010812.htm | 0000947871-26-000749 |
| Document: 0001231919-26-000833-index-headers.html | 0000947871-26-000749 |
| Document: 0001231919-26-000833-index.html | 0000947871-26-000749 |
| Document: 0001231919-26-000833.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 33 | 0001470831-26-000780 |
| Document: 0001470831-26-000780-index-headers.html | 0000947871-26-000749 |
| Document: 0001470831-26-000780-index.html | 0000947871-26-000749 |
| Document: 0001470831-26-000780.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 37 | 0001470831-26-000779 |
| Document: 0001470831-26-000779-index-headers.html | 0000947871-26-000749 |
| Document: 0001470831-26-000779-index.html | 0000947871-26-000749 |
| Document: 0001470831-26-000779.txt | 0000947871-26-000749 |
| 3 Filing (BRVE) — Batch item 41 | 0001470831-26-000778 |
| Document: 0001470831-26-000778-index-headers.html | 0000947871-26-000749 |
| Document: 0001470831-26-000778-index.html | 0000947871-26-000749 |
| Document: 0001470831-26-000778.txt | 0000947871-26-000749 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 3 | $27.66 $26.71 | ▼ −3.43% | ▼ −1.46% | $21.82 (−21.11%) |
Aug 11, 2026 10w ago | Insider Cluster | $26.15 $27.25 | ▲ +4.21% | ▲ +6.10% | $21.82 (−16.56%) |
Aug 11, 2026 10w ago | Insider Cluster | $26.15 $27.25 | ▲ +4.21% | ▲ +6.10% | $21.82 (−16.56%) |
Aug 7, 2026 11w ago | Insider Cluster | $27.53 $29.41 | ▲ +6.83% | ▲ +7.74% | $21.82 (−20.74%) |
Aug 7, 2026 11w ago | Insider Cluster | $27.53 $29.41 | ▲ +6.83% | ▲ +7.74% | $21.82 (−20.74%) |
Aug 5, 2026 11w ago | Press Release | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.82 (−26.78%) |
Aug 5, 2026 11w ago | 3 | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.82 (−26.78%) |
Aug 5, 2026 11w ago | 3 | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.82 (−26.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers